Aurobindo Pharma Limited Fundamentals

    Aurobindo Pharma Limited takes part in the exploration, improvement, production, and offer of dynamic drug fixings, conventional drugs, and related administrations in India. The organization essentially offers oral solids, injectables, over the counter medications, and dietary enhancements, just as dynamic drug fixings and completed measurement structures for cardiovascular, focal sensory system, gastroenterology, enemies of hypersensitivities, enemies of diabetics, hostile to retroviral, anti-microbials, dermatology, respiratory, and oncology. It is additionally associated with the advancement of an item pipeline in biosimilar and antibody portions; and custom examination and assembling exercises for the bio-tech and drug local area. Also, the organization creates and produces peptides, just as biocatalysts for use in the drug and substance businesses. Further, it is creating biosimilar, inhalers, transdermal patches, antibodies, topicals, and terminal infusions. The organization additionally sends out its items. It serves global organizations. The organization has a concurrence with COVAXX to create and market Coronavirus Antibody for India and UNICEF. Aurobindo Pharma Limited was consolidated in 1986 and is settled in Hyderabad, India..

    Business space of the organization 

    Aurobindo Pharma keeps on being one of the world's quickest developing Dynamic Drug Fixings (Programming interface) fabricating organizations, driven by cost administration, adaptability to create numerous items in similar assembling offices and capacities in different helpful spaces. Its Programming interface business has guaranteed the productivity and development of its details business through consistent vertical reconciliation. Its Programming interface business is upheld by innovatively progressed innovative work foundation, which grows new items and assumes a part in the conveyance of items to the market. It has assembled a solid presence in key restorative portions, for example, Focal sensory system (CNS), cardiovascular (CVS), against retroviral (ARV), enemies of diabetics, gastroenterology and anti-toxins. Additionally, it is building a differentiated pipeline in high-edge claim to fame conventional plans section.

    Awards and Recognition


    The company was honoured in January 2016, the Indian Drug Manufacturers'' Association IDMA Margi Memorial Best Process Patent Award 2014-15 for three US patents.
    The Pharmaceuticals Export Promotion Council of India (Pharmexcil) conferred upon the company a
    Certificate of Appreciation in recognition of commendable contribution in bulk/APIs category.
    The Chief Commissioner of Central Excise, Customs and Service Tax, Hyderabad felicitated the company in February 2016 for outstanding performance during the financial year 2014-15.


    Certificate of Honor in the category of Excellence in HR by CPhI India & UBM India for the initiatives taken for e-learning, skill development, HR automation, talent engagement, leadership competencies & its integration with HR sub-systems.
    Certificate of Appreciation in the 12th edition of BML Munjal Awards for Excellence in Learning & Development.
    Received an award for Most Consistent IR (Investor Relations) Practice in Large Cap category for 2016-17 conducted by KPMG, BSE, Bloomberg and IR Society.
    Winner of the Clarivate Analytics India Innovation Awards 2016.


    Received ‘Pharmexcil Outstanding Exports Award 2016- 17’ in the category of highest Number of ANDAs filed in the calendar year 2016.
    Bagged two Awards in ‘Excellence in Skill Development’ & ‘Excellence in Pharma Digital Innovation’ for the 2nd time in row at the India Pharma Awards 2017 in South-Asia’s largest pharmaceutical event- CPhI& PMEC India.
    Won the ‘IDMA MARGI MEMORIAL BEST PROCESS PATENTS AWARD 2016-17’ (for 2 Indian & 1 US Granted patents; supported by several other patent applications filed during the said year) awarded by Indian Drug Manufacturers’ Association.
    Received ‘2017 Business Award; from The East Windsor Township for best community enhancement contributions in East Windsor Township.
    Aurobindo’s Unit 15 at Parawada - Vizag awarded by the State Government of Andhra Pradesh for best management award in manufacturing sector.


    Aurobindo has been awarded IP Excellence in INDIA 2018 by Questel Orbit INC, as a part of their Indian IP Awards, 2018. The Indian IP Awards are given to facilitate best professionals across the IP (Intellectual Property) Industry.
    Bagged award for the category of Best CSR Practices in Responsible Business Awards hosted by World CSR Day.
    Bagged the ''Outstanding Export Award for FY2017-18'' conducted by Pharmaceutical Export Promotion Council of India (Pharmexcil).
    Received ‘IDMA Best API Patents Award 2017- 18’ conducted by Indian Drug Manufacturers association.
    The Federation of Telangana and Andhra Pradesh Chamber of Commerce and Industry (FTAPCCI) has felicitated Aurobindo with HR Best Practices Awards-2018 in the category of Large-Scale Industries.


    Bagged the coveted 14th National BML Munjal Award for ’Business Excellence through Learning & Development’ in the Private Sector Manufacturing category from Bharat Ratna Pranab Mukherjee, Former President of India.
    Aurobindo Unit-III has bagged the Special Commendation Award in the Golden Peacock Environmental Management Awards 2019 from the Institute of Directors (IOD). These awards are regarded as a benchmark of corporate excellence worldwide.
    Aurobindo has been awarded as Best Energy Efficient Organization under Large Scale Industry Category in CII’s 4th edition of National Energy Efficiency Circle Competition.

    Major Events and Milestones

    1986: Aurobindo Pharma (APL) one of the world’s top 5 manufacturers of semi synthetic penicillins was incorporated in December 26, 1986 as a private limited company by P.V.Ramprasad Reddy and K.Nityananda Reddy.
    1988-1989: Commenced operations with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry.
    1992-1993: Another unit was established for the manufacture of CMIC Chloride, a bulk drug intermediate, at pashmylaram near Hyderabad.
    1994-1995: Merged with Chaitanya Organics. Commercial production of the pharmaceutical formulation unit started in April.
    1994-1995: Aurobindo Pharma became a public company in 1995.
    1997-1998: Glaxo (India) the Indian subsidiary of the UK-based multinational formed an alliance with the company to meet its global bulk drug requirements.
    1999-2000: Diversified product portfolio further with the introduction of wide range of Cephalosporins (Oral & Sterile) and anti – virals in addition to macrolides, anti-ulcerants, quinolones, semi-synthetic penicillins, and formulations for domestic and export market.
    1999-2000: Joint Ventures launched for formulations business in US.
    1999-2000: Sri Chakra Remedies was amalgamated with the company.
    2001-2002: Launched an exclusive anti-viral division Immune to educate and to provide preventive drug care for HIV/AIDS patients in the country.
    2001-2002: Launched two more drugs in 2001 namely Efavirenz (Viranz) and Nelfinavir (NELVEX) for the treatment of AIDS.
    2001-2002: Acquired 79% stake in Ranit Pharma Company under the same management. Ranit Pharma and Calc Private were amalgamated with APL as of April 1, 2002.
    2003-2004: JV between APL and Shanxi Tongling Pharmaceuticals launched under the name Aurobindo Tongling (Datong) pharmaceuticals China.
    2003-2004: Aurobindo’s 100% subsidiary company in China commenced commercial production.
    2003-2004: Aurobindo received its first Certificate of Suitability (CoS) approval from the European Directorate for Quality Medicines (EDQM).
    2004-2005: Acquired a sterile plant of Dee Pharma.
    2004-2005: The State Labour Department of the Government of Andhra Pradesh awarded Aurobindo the ‘Best Management Award’ in 2005 for the company’s contributions towards community development, harmonious employee relations and employee welfare.
    2004-2005: US FDA unit of US Department of Health and Human Science approved the company’s Unit VIII facility and received US FDA clearance for AIDS drugs.
    2005-2006: Aurobindo made a strategic entry into the premium markets of USA & Europe with generic formulations, participating in the PEPFAR program initiated by the Government of USA.
    2005-2006: APL acquired UK based Milpharm Limited, engaged in marketing generic formulations in the UK market.
    2007-2008: Aurobindo unveiled a new Logo and Corporate Identity at a ceremony in Hyderabad. The new corporate logo reflects the company’s pace of innovation and its industry leadership.
    2007-2008: Acquired intellectual property & marketing authorizations with TAD Italy, a generic company registered in Italy, to get an access to more than 70 ready to market products.
    2010-2011: Entered into licensing and supply agreements with AstraZeneca, one of the world’s leading biopharmaceutical companies to supply several solid dosage and sterile products for emerging markets.
    2010-2011: Agreement signed with China National Pharmaceutical Group Corporation (Sinopharm) to divest a majority stake in subsidiary company Aurobindo (Datong) Bio Pharma Co China (ADBPL).
    2014 -2016: Acquired certain commercial operations in Western Europe from Actavis Plc., a global, integrated specialty pharmaceutical company.
    2014 -2016: Acquired assets of nutritional supplement maker Natrol Inc. and other affiliate entities (Natrol) through its wholly owned subsidiary Aurobindo Pharma USA Inc. (APUSA).
    2014 -2016: Arrow Generiques SAS, a French subsidiary of APL announced the signing of an agreement to acquire the rights title and interest in its products Calcium and Calcium Vitamin D3 in France including the use of the OROCAL trademark from Teva Pharmaceutical Industries.
    2017-2018: Signed a definitive agreement to acquire dermatology and oral solids businesses from Sandoz Inc., USA.
    2017-2018: Signed a definitive agreement to acquire Apotex Inc’s commercial operations in 5 European countries.
    2017-2018: Started filing Oncology & Hormones, Dermatology and Nasal ANDAs in US.
    2017-2018: Acquired Generis in Portugal - Focus on differentiated technology platforms and Specialty Pharmaceuticals.
    2017-2018: Acquired four cell-culture derived biosimilar products from TL Biopharmaceutical AG.
    2018-19: Signs a definitive agreement to acquire Apotex’ Businesses in Poland, Czech Republic, the Netherlands, Spain and Belgium.
    2019-20: Receives USFDA Approval for Guaifenesin Extended-Release Tablets (OTC).
    2019-20: The company’s JV Eugia Pharma receives USFDA Approval for Methotrexate Tablets

    AUROPHARMA Limited Stock Price Analysis and Quick Research Report

    Let’s scrutinize however AUROPHARMA is acting and if it's the proper time to buy the stock of  AUROPHARMA with careful analysis.

    The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

    Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

    Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
    Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
    Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals. While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Aurobindo Pharma and its performance over the period of time.

    Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 2,994.41 Cr.
    Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Aurobindo Pharma has a Debt to Equity ratio of 0.25 , which is a strong indication for the company.
    EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Aurobindo Pharma , the EPS growth was 65.86 % which is good for the company.
    Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Aurobindo Pharma has OPM of 26.04 % which is a good sign for profitability.
    ROE: Aurobindo Pharma have a healthy ROE of 21.49 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.


    AUROPHARMA Mini Live Chart


    AUROPHARMA Technical 

    NOTE: We might update this page with latest updates/information/news etc if it deems to be necessary.

    Thank You


    To Top